117 related articles for article (PubMed ID: 19945303)
1. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate.
Bittner N; Merrick GS; Stewart R; Andreini H; Taubenslag W; Curtis R; Butler WM; Wallner KE
Urol Oncol; 2011; 29(4):398-404. PubMed ID: 19945303
[TBL] [Abstract][Full Text] [Related]
2. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
3. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy.
Bittner N; Merrick GS; Butler WM; Bennett A; Galbreath RW
J Urol; 2013 Aug; 190(2):509-14. PubMed ID: 23416641
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.
Merrick GS; Gutman S; Andreini H; Taubenslag W; Lindert DL; Curtis R; Adamovich E; Anderson R; Allen Z; Butler W; Wallner K
Eur Urol; 2007 Sep; 52(3):715-23. PubMed ID: 17337114
[TBL] [Abstract][Full Text] [Related]
5. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
6. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
7. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies.
Gershman B; Zietman AL; Feldman AS; McDougal WS
Urol Oncol; 2013 Oct; 31(7):1093-7. PubMed ID: 22305626
[TBL] [Abstract][Full Text] [Related]
8. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience.
Barzell WE; Melamed MR
Urology; 2007 Dec; 70(6 Suppl):27-35. PubMed ID: 18194708
[TBL] [Abstract][Full Text] [Related]
9. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
[TBL] [Abstract][Full Text] [Related]
10. Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.
Merrick GS; Delatore A; Butler WM; Bennett A; Fiano R; Anderson R; Adamovich E
Am J Clin Oncol; 2017 Feb; 40(1):53-59. PubMed ID: 25068472
[TBL] [Abstract][Full Text] [Related]
11. The morbidity of transperineal template-guided prostate mapping biopsy.
Merrick GS; Taubenslag W; Andreini H; Brammer S; Butler WM; Adamovich E; Allen Z; Anderson R; Wallner KE
BJU Int; 2008 Jun; 101(12):1524-9. PubMed ID: 18325064
[TBL] [Abstract][Full Text] [Related]
12. Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy.
Lee CU; Sung SH; Jang CT; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Urol Int; 2019; 103(3):262-269. PubMed ID: 31269509
[TBL] [Abstract][Full Text] [Related]
13. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Performance of Initial Transperineal Template-guided Mapping Biopsy of the Prostate Gland.
Bittner N; Merrick GS; Bennett A; Butler WM; Andreini HJ; Taubenslag W; Adamovich E
Am J Clin Oncol; 2015 Jun; 38(3):300-3. PubMed ID: 23764680
[TBL] [Abstract][Full Text] [Related]
15. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
Siddiqui SA; Inman BA; Sengupta S; Slezak JM; Bergstralh EJ; Leibovich BC; Zincke H; Blute ML
Cancer; 2006 Aug; 107(3):521-9. PubMed ID: 16773619
[TBL] [Abstract][Full Text] [Related]
16. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
18. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
19. Location and Grade of Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy After Negative Transrectal Ultrasound-guided Biopsy.
Bittner N; Merrick G; Taira A; Bennett A; Schattel A; Butler W; Galbreath R; Adamovich E
Am J Clin Oncol; 2018 Aug; 41(8):723-729. PubMed ID: 27906722
[TBL] [Abstract][Full Text] [Related]
20. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
Bittner N; Merrick GS; Butler WM; Galbreath RW; Anderson RL; Adamovich E; Wallner KE
Brachytherapy; 2012; 11(3):219-23. PubMed ID: 21820364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
